• John Piacentini, Shannon Bennett, Scott N Compton, Phillip C Kendall, Boris Birmaher, Anne Marie Albano, John March, Joel Sherrill, Dara Sakolsky, Golda Ginsburg, Moira Rynn, R Lindsey Bergman, Elizabeth Gosch, Bruce Waslick, Satish Iyengar, James McCracken, and John Walkup.
• University of California-Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior. Electronic address: jpiacentini@mednet.ucla.edu.
• J Am Acad Child Adolesc Psychiatry. 2014 Mar 1; 53 (3): 297-310.

ObjectiveWe report active treatment group differences on response and remission rates and changes in anxiety severity at weeks 24 and 36 for the Child/Adolescent Anxiety Multimodal Study (CAMS).MethodCAMS youth (N = 488; 74% ≤ 12 years of age) with DSM-IV separation, generalized, or social anxiety disorder were randomized to 12 weeks of cognitive-behavioral therapy (CBT), sertraline (SRT), CBT+SRT (COMB), or medication management/pill placebo (PBO). Responders attended 6 monthly booster sessions in their assigned treatment arm; youth in COMB and SRT continued on their medication throughout this period. Efficacy of COMB, SRT, and CBT (n = 412) was assessed at 24 and 36 weeks postrandomization. Youth randomized to PBO (n = 76) were offered active CAMS treatment if nonresponsive at week 12 or over follow-up and were not included here. Independent evaluators blind to study condition assessed anxiety severity, functioning, and treatment response. Concomitant treatments were allowed but monitored over follow-up.ResultsThe majority (>80%) of acute responders maintained positive response at both weeks 24 and 36. Consistent with acute outcomes, COMB maintained advantage over CBT and SRT, which did not differ, on dimensional outcomes; the 3 treatments did not differ on most categorical outcomes over follow-up. Compared to COMB and CBT, youth in SRT obtained more concomitant psychosocial treatments, whereas those in SRT and CBT obtained more concomitant combined (medication plus psychosocial) treatment.ConclusionsCOMB maintained advantage over CBT and SRT on some measures over follow-up, whereas the 2 monotherapies remained indistinguishable. The observed convergence of COMB and monotherapy may be related to greater use of concomitant treatment during follow-up among youth receiving the monotherapies, although other explanations are possible. Although outcomes were variable, most CAMS-treated youth experienced sustained treatment benefit. Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); URL: http://clinicaltrials.gov. Unique identifier: NCT00052078.Copyright © 2014 American Academy of Child and Adolescent Psychiatry. All rights reserved.

23 keywords...

hide…